This Global #FattyLiverDay, we welcomed Kim and Bruce who shared their personal experiences living with #NASH / #MASH. It’s stories like these that keep us driven in our efforts toward fighting this disease. Learn about our progress in NASH: https://bit.ly/49gCAgl.
Madrigal Pharmaceuticals
Pharmaceutical Manufacturing
Conshohocken, Pennsylvania 41,536 followers
Madrigal is focused on developing therapeutics to improve the lives of patients with metabolic and fatty liver diseases.
About us
Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) is a clinical-stage biopharmaceutical company pursuing novel therapeutics for non-alcoholic steatohepatitis (NASH), a liver disease with high unmet medical need. Madrigal’s lead candidate, resmetirom, is a once daily, oral, thyroid hormone receptor (THR)-β selective agonist that is designed to target key underlying causes of NASH in the liver. Resmetirom is currently being evaluated in two Phase 3 clinical studies, MAESTRO-NASH and MAESTRO-NAFLD-1, designed to demonstrate multiple benefits in patients with NASH. For more information, visit www.madrigalpharma.com.
- Website
-
https://www.madrigalpharma.com/
External link for Madrigal Pharmaceuticals
- Industry
- Pharmaceutical Manufacturing
- Company size
- 51-200 employees
- Headquarters
- Conshohocken, Pennsylvania
- Type
- Public Company
- Founded
- 2016
- Specialties
- Liver Disease, NASH, and Metabolic Disease
Locations
-
Primary
Get directions
200 Barr-Harbor Dr
Suite 200
Conshohocken, Pennsylvania 19428, US
Employees at Madrigal Pharmaceuticals
Updates
-
We are proud to sponsor Global Liver Institute's Global #FattyLiverDay, an awareness initiative that prioritizes the lives of those impacted by #NASH / #MASH. Help us increase education by joining the conversation.
This Global #FattyLiverDay hear from our Founder and CEO, Donna Cryer, as she shares what today can mean for patients with #FattyLiverDisease. Learn more: https://lnkd.in/gwNfFW3e #ActNowScreenToday #Liverhealth #FattyLiver #NASH #MASH
-
-
Advocates like Susan remind us why our research and innovative efforts play a critical role in the lives of people living with fatty liver disease. This Global #FattyLiverDay, please take the time to listen to Susan’s hope for the #NASH / #MASH community.
-
On Global #FattyLiverDay, our CEO Bill Sibold expresses his gratitude for the #NASH / #MASH community, reminding us the role we can all play in the fight against liver disease.
It’s been a tremendous year filled with so much progress and excitement for the #NASH / #MASH community. As we recognize Global #FattyLiverDay, I want to take a moment to thank and acknowledge this resilient community. Your experiences, stories and advice serve as inspiration for all of us at Madrigal Pharmaceuticals as we navigate and tackle the challenges of NASH together. We’ve made significant strides over the last few months and we're just getting started. Days like today serve as a reminder of our collective responsibility to raise awareness and educate those around us on the seriousness of NASH. Even the smallest efforts and changes can have a big impact on helping improve health outcomes for patients living with NASH. Together, we will continue pushing the boundaries in our fight against #LiverDisease!
-
Honoring Global Liver Institute’s Global #FattyLiverDay, we want to thank the #NASH / #MASH community for its continued efforts in helping those living with this disease. Our Madrigal team remains committed to those who share the same mission in raising awareness, promoting education and fostering support to help create healthier, happier lives.
-
Following the conclusion of #EASL2024, Madrigal CEO, Bill Sibold, recaps his first ever EASL | The Home of Hepatology Annual Congress and expresses his gratitude to the #NASH / #MASH community. If you attended, please share a favorite moment from the #EASLCongress in the comments below!
-
-
For those attending the EASL | The Home of Hepatology Annual Congress, we encourage you to stop by booth J1 to meet our team and learn more. We’re excited to connect with the #hepatology community at #EASL2024. #EASLCongress
-
-
Today we announced new data being presented at this year's EASL | The Home of Hepatology Annual Congress. Learn more: https://bit.ly/3Rgt6Md #EASL2024 #EASLCongress
-
We’re proud to contribute to research that helps drive progress in #NASH / #MASH at this year’s EASL | The Home of Hepatology Annual Congress. We’re excited to meet with the #hepatology community at the event. #EASL2024 #EASLCongress
-
-
We’re excited to attend the EASL | The Home of Hepatology Annual Congress, where we will be sharing the latest data in #NASH / #MASH and hosting a booth. Learn more by reading our press release: https://bit.ly/3WZ6Cmv #EASL2024 #EASLCongress